CRISPR Therapeutics (NASDAQ: CRSP)
$37.75
(-3.1%)
-$1.20
Price as of April 16, 2025, 3:58 p.m. ET
CRISPR Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
CRISPR Therapeutics Company Info
CRISPR Therapeutics is a biotech company using gene therapy to try to correct genetic mutations to treat and cure diseases.
News & Analysis
The Fool has written over 400 articles on CRISPR Therapeutics.
Featured Article
3 Magnificent Stocks That Could Double or More by 2030
Keith Speights, David Jagielski, and Prosper Junior Bakiny | Apr 12, 2025
Featured Article
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Adria Cimino | Apr 11, 2025
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
Prosper Junior Bakiny | Apr 7, 2025
2 Beaten-Down Stocks to Buy on the Dip
Prosper Junior Bakiny | Mar 22, 2025
Investing in Gene-Editing Stocks
Keith Speights | Mar 20, 2025
Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why
Motley Fool YouTube | Feb 28, 2025
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
Prosper Junior Bakiny | Feb 24, 2025
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
Eric Volkman | Feb 12, 2025
Valuation
Podcast Episodes
"The Era of the Gene-Edited Human Is Here"
An investor's look.
Chris Hill | Sep 19, 2022
Breaking Down CRISPR Technology
What investors need to know.
Karl Thiel | Sep 28, 2021
Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Todd Campbell | Nov 22, 2019
Did China’s “Designer Babies” Just Open Pandora’s Box?
What will this mean for healthcare and for the future of society?
Motley Fool Staff | Dec 21, 2018
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.